Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2-Reference-Cited by-同舟云学术

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2

Published:2002-07 Issue:1 Volume:54 Page:25-32
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Le Brun P.P.H,de Boer A.H,Mannes G.P.M,de Fraı̂ture D.M.I,Brimicombe R.W,Touw D.J,Vinks A.A,Frijlink H.W,Heijerman H.G.M

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference18 articles.

1. Inhalation of antibiotics in cystic fibrosis;Touw;Eur. Respir. J.,1995

2. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks;Mukhopadhyay;Thorax,1996

3. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus;Doring;Eur. Respir. J.,2000

4. Inhaled micronised gentamicin powder: a new delivery system;Goldman;Thorax,1990

5. Comparative evaluation of preliminary in vitro deposition results for tobramycin from WISTO Senior® nebulizer and two different dry powder inhalers;Touw,1996

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies;DARU Journal of Pharmaceutical Sciences;2024-06-11

2. The quest to deliver high-dose rifampicin: can the inhaled approach help?;Expert Opinion on Drug Delivery;2024-01-02

3. Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers;PLOS ONE;2022-08-05

4. Rescuing the Last-Line Polymyxins: Achievements and Challenges;Pharmacological Reviews;2021-02-24

5. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations;International Journal of Pharmaceutics;2020-12